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[57] ABSTRACT 
The present invention is directed to novel seco-cholestane 
derivatives, as well as to pharmaceutical compositions 
thereof, and methods of making the same. More particularly, 
the invention relates to CS- and CS-substituted seco-
cholestane derivatives. The compounds of the invention can 
exhibit CDC25 phosphatase inhibition properties and anti-
cancer activity. 
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SECO-CHOLESTANE DERIVATIVES AND 
METHODS OF MAKING THE SAME 
2 
human oncogenes, Science, 199S, 269, 1S7S-1S77; 
Gasparotto, D. et al., Overexpression of CDC2SA and 
CDC2SB in head and neck cancers, Cancer Res, 1997, S7, 
2366-236S; Galaktionov, K., et al., Cdc2S cell-cycle phos-The present invention was made with Government sup-
port under Grant No. CA5299S from the National Institutes 
of Health. The Government has certain rights to this inven-
tion. 
FIELD OF THE INVENTION 
5 phatase as a target of c-myc, Nature, 1996, 3S2, Sll-Sl 7; 
Hernandez, S. et al., cdc2S cell cycle-activating phos-
phatases and c-myc expression in human non-Hodgkin's 
lymphomas, Cancer Res 199S, SS(S):1762-1767. Thus 
increased CDC2SA activities may contribute to the dysregu-
The present invention relates to novel seco-cholestane 
derivatives and methods of making the same. More 
particularly, the invention relates to ring-opened, CS- and 
CS-substituted seco-cholestane derivatives having CDC2S 
phosphatase inhibition properties and anti-tumor activities. 
10 lated growth of certain types of tumor cells. Both CDC2SA 
and B phosphatases are considered promising target 
enzymes for the development of anti-cancer drugs. Draetta, 
G. and Eckstein, J. W., Cdc2S protein phosphatases in cell 
proliferation, Biochimica et Biophysica Acta, 1997, 1332, 
15 MS3-M63. 
BACKGROUND OF THE INVENTION 
The survival and functioning of cells relies on the elabo-
rate intercellular and intracellular communication network 
known as signal transduction pathways. These pathways 
coordinate proliferation, differentiation, metabolism, cell 
adhesion and motility, protein sorting and transportation of 
multitudes of cells in different tissues and organs. The 
malfunctions of these pathways can result in many diseases 
such as cancer and rheumatoid arthritis. Therefore, great 
25 
effort has been focused on the development of therapies 
based on blocking cellular signaling in the diseased cells. 
Levitzki, A, Targeting signal transduction for disease 
therapy, Current Opinion in Cell Biology, 1996, S, 239-244. 
Although CDC2S phosphatases have been identified as 
playing a crucial role in the replication cycle of cancer cells, 
studies of the intracellular function of CDC2S phosphatases 
have been severely hampered by the lack of potent inhibi-
20 tors. To date few therapeutic agents have been reported as 
specific targets for these enzymes or as inhibitors of their 
activity. Vanadate, a broad-spectrum protein phosphatase 
inhibitor was the first CDC2SAinhibitor found. Baratte B. et 
Intracellular signaling is a series of coupled events that 30 
transduce stimuli from outside of the cell into the cell. The 
signals are relayed by different sets of signal transducer 
proteins in a sequential fashion, and result in cellular 
responses. In this process, post-translational modifications 
al., Screening for antimitotic compounds using the cdc2S 
tyrosine phosphatase, an activator of the mitosis-inducing 
p34cdc2/cyclin Bcdcl3 protein kinase, Anticancer Res 
1992, 12(3):S73-SSO. In 1996, the natural product dysid-
iolide was reported as a cdc2SAinhibitor with an IC50 value 
of proteins by addition and removal of phosphate groups 
provide molecular switches to turn on and turn off the 
function of various transducer proteins. A broad family of 
protein phosphatases catalyzes the removal of phosphate 
groups from serine, threonine or tyrosine residues on pro-
teins. 
of 9.4 µM. Gunasekera, S. P. et al., Dysidiolide: A Novel 
Protein Phosphatase inhibitor from the Caribbean Sponge 
Dysidea ehteria de Laubenfels, J.Am.Chem.Soc. 1996, llS, 
S7S9-8760. Later, Rice and coworker also synthesized a 
group of inhibitors based on the pharmacophore of protein 
tyrosine phosphatase (PTPase) inhibitors. Rice, R. L. et al., 
35 A targeted Library of Small-Molecule, Tyrosine, and Dua/-
Specificity Phosphatase Inhibitors Derived from a Rational 
Core Design and Random Side Chain Variation, 
Biochemistry, 1997, 36, 1S96S-1S974. This series of com-
pounds inhibited CDC2SA phosphatase competitively, the 
40 
most potent inhibitor having an IC50 value of lS µM. CDC2S comprises a family of dual specificity protein 
phosphatases which act to remove inhibitory phosphates 
from cdk kinases and activate cyclin dependent kinase 
complexes that trigger cell cycle progression. Sadhu, K. et 
al., Human homolog of fission yeast cdc2S mitotic inducer is 45 
predominantly expressed in G2, Proc. Nat. Acad. Sci. U.S.A. 
1990, S7, S139-S143; Galaktionov, K. and Beach, D., Spe-
cific activation of cdc2S tyrosine phosphatases by B-type 
cyclins: evidence for multiple roles of mitotic cyclins, Cell 
1991, 67, llSl-1194. In human cells, CDC2S consists of 50 
three phase specific isoforms, CDC2SA, B and C. CDC2SA 
As discussed above, the dual specificity protein phos-
phatase (CDC2SA) plays a crucial role in cancer cell 
proliferation, and there exists a need for efficient synthetic 
routes for more potent CDC2SA inhibitors. However, the 
total synthesis of natural products is usually lengthy, and 
with lower yields. Readily available natural products, with 
defined stereochemistry and useful functional groups, can be 
utilized with novel and efficient chemical transformations to 
solve the difficult problems. The pyrolysis of alkyl azides to 
form cyano groups has been reported. Bock, H. and 
Dammel, R., Gas-Phase Pyrolysis of Alkyl Azide: Experi-
mental Evidence for Chemical Activation, J.Am.Chem.Soc. 
19SS, 110, S261-S269. However, no report has appeared on 
is expressed early in the G1 phase of the cell cycle, and is 
essential for transition from G1 to S phase. Jinno, S. et al., 
Cdc2SA is a novel phosphatase functioning early in the cell 
cycle, EMBO J, 1994, 13, 1S49-1SS6. 55 the pyrolysis of azido-steroids on the surface of silica gel. 
The activation of at least two cyclin-dependent kinases, 
required for Gl to S phase progression, depends on the 
dephosphorylation of the catalytic cdk subunit at Tyr-lS and 
Thr-14 near the ATP-binding site. The phorsphorylation of 
these two residues blocks the binding of ATP to the cyclin- 60 
cdk complex and renders the complex catalytically inactive. 
The dephorsphorylation of both cyclin E-cdk2 and cyclin 
A-cdk2 complexes by CDC2SA is tightly regulated in nor-
mal cells. Accumulating evidence suggests that inappropri-
ate amplification or activation of CDC2SA is characteristic 65 
of a number of cancers, including breast cancer. 
Galaktionov, K. et al, CDC2S phosphatases as potential 
SUMMARY OF THE INVENTION 
The present invention relates to the discovery of a group 
of novel seco-cholestane derivatives possessing pharmaceu-
tical activities, including CDC2S phosphatase inhibition 
properties, and tumor cell growth inhibition activities. The 
present invention also relates to the discovery of an efficient 
synthetic route to CS- and CS- substituted seco-cholestane 
derivatives of Formula (I), by pyrolyzing readily available 
azido-cholestane precursors with the option of introducing 
functionality as needed. 
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A first aspect of the present invention is directed to CS-
and CS-substituted seco-cholestane derivatives of the For-
mula (I) 
wherein: 
R1 is selected from the group consisting of H, lower alkyl, 
and alkoxy; 
R2 is selected from the group consisting of Cl-ClO alkyl, 
substituted Cl-ClO alkyl, C2-C10 alkene containing one to 
four double bonds, substituted C2-C10 alkene, and Cl-ClO 
alkyl or C2-Cl0 alkene having one or more heteroatoms 
selected from the group consisting of oxygen atoms and 
nitrogen atoms inserted into the chain thereof, the chain 
having 10 or less atoms including the hetero atoms; 
5 
10 
4 
wherein: 
R1 , R2 , R3 , R4 , R6 , and Y are the same as defined above, 
and R7 is a substituent introduced by Michael Addition of 
nucleophiles to the double bond between C3 and C4 when 
15 present, such as, but not limited to hydroxy, lower alkoxy, 
e.g., methoxy, lower alkanoyloxy, e.g., acetoxy, amino, 
lower alkyl amino, e.g. methyl amino, carboxyl, acetylene, 
cyano, lower alkyl, lower alkene, cycloalkyl, e.g., 
cyclopropyl, and the like. In this embodiment of the 
20 invention, Rs is C4 alkyl or C4 alkene having one or more 
double bonds as indicated by the dotted lines. Further, in this 
embodiment of the invention, Y can be ---(CH2)-C(O)-
O- and together with the CS atom to which Y is attached, 
R3 is selected from the group consisting of methylene, 25 
ketone, and methyl; 
C9, ClO, Cl, C2 and C3 atoms, constitute a nine membered 
lactone ring. Still further, in this embodiment of the 
invention, R4 can be oxygen and together with C3 and ClO 
R4 is absent when R3 is methylene or ketone, or when R3 
is methyl, R4 is selected from the group consisting of 
hydrogen, lower alkyl, alkoxy, lower alkanoyloxy, hydroxy, 
carboxyl, amino, lower alkylamino, and halo, or R4 is an 
oxygen atom and together with the ClO atom to which R4 is 
attached and Rs comprises a heterocyclic ring and the 
double bond between ClO and R3 , C9 and ClO, or ClO and 
Rs is absent; 
to which it is attached, and Cl and C2, constitute a five 
membered tetrahydrofuran ring. 
Another aspect of the present invention includes methods 
30 for synthesizing the seco-cholestane derivatives of Formula 
(I). In this aspect of the invention, 3-a-azido-B-homo-6-
oxa-4-cholesten-7-one is heated under conditions sufficient 
to open rings A and B thereof and to provide a chain 
containing a conjugated cyano group, while leaving the 
35 cholesteryl C and D rings and the side chain intact. The 
method further includes optional hydrogenation or 
hydrolysis/Michael Addition steps. 
Y is Cl-C6 alkyl or C2-C6 alkene terminating in an 
amide group -CONH2 , a nitrile group -CN, or an acid 
group, including, but not limited to, a carboxylic acid group 
C02 H, a sulfonic acid group S03H, a carbodithioic acid 
group -CSSH, or a phosphoric acid group PO(OH)2 , or 40 
salts of these acidic groups, or 
The invention also provides pharmaceutical compositions 
comprising the seco-cholestane derivatives of Formula (I) 
and one or more pharmaceutically acceptable carriers or 
diluents. 
Yis-(CH2)n-C(O)-X-, wherein n is an integer from 
1 to 3, X is oxygen or nitrogen, and together with CS atom 
to which Y is attached, the C9 atom, and the ClO atom 45 
constitute a ring system comprising a 6 to S membered 
lactone or lactam ring, or 
BRIEF DESCRIPTION OF THE DRAWINGS 
In the drawings which form a portion of the disclosure of 
the invention: 
FIG. 1 illustrates a general reaction Scheme 1 for prepar-
ing the compounds of Formula (I); Y is -(CH2)-C(O)-O-, and together with the CS 
atom to which Y is attached, the C9 atom, the ClO atom, and 
Rs constitute a ring system comprising a lactone ring when 
R3 is methyl, R4 is hydroxyl and the double bond between 
ClO and R3 , Rs and ClO or C9 and ClO is absent; 
50 
FIG. 2 illustrates one embodiment of the invention, 
namely, Scheme 2 illustrating the pyrolysis of the precursor 
3a-azido-B-homo-6-oxa-4-cholesten-7-one on silica gel; 
FIG. 3 illustrates the optional hydrogenation of the 
pyrolysis products of FIG. 2; Rs is selected from the group consisting of C2-CS alkyl, C2-CS alkene having one or more double bonds, substituted 
C2-CS alkyl, and substituted C2-CS alkene; 55 FIG. 4 illustrates the optional steps of base catalyzed 
hydrolysis and intramolecular Michael addition of the 
pyrolysis products of FIG. 2 and the hydrogenation products 
of FIG. 3; 
R6 is a functional group selected from the group consist-
ing of CN, COOH, CSSH, or salts of these acid groups, 
CHO, CH2 0H, CONH2 , and CONR2 , wherein R is lower 
alkyl, acyl or H, and optionally a hydrogen atom of a carbon 
atom adjacent R6 may be replaced with identical functional 
groups described above; and 
the broken lines indicate optional double bonds, and 
pharmaceutically acceptable salts of the compounds of For-
mula (I). 
In one preferred embodiment of the invention, the com-
pounds of the invention have the formula (Ia): 
FIG. 5 illustrates the synthesis of the pyrolysis precursors 
60 3a-azido-B-homo-6-oxa-4-cholesten-7-one of FIG. 2; 
65 
FIG. 6 is a graph illustrating the inhibition of HT-29 colon 
cancer cells by seco-cholestane derivatives of the invention; 
and 
FIG. 7 is a graph illustrating the inhibition of A459 lung 
adenocarcinoma cells by a seco-cholestane derivative of the 
invention. 
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DETAILED DESCRIPTION OF IBE 
INVENTION 
The present invention is directed to compounds of For-
mula (I) 
wherein: 
R1 is selected from the group consisting of H, lower alkyl, 
and alkoxy; 
R2 is selected from the group consisting of Cl-ClO alkyl, 
substituted Cl-ClO alkyl, C2-C10 alkene containing one to 
four double bonds, substituted C2-C10 alkene, and Cl-ClO 
alkyl or C2-Cl0 alkene having one or more heteroatoms 
selected from the group consisting of oxygen atoms and 
nitrogen atoms inserted into the chain thereof, the chain 
having 10 or less atoms including the hetero atoms; 
6 
respectively. The term "lower alkyl" refers to Cl-C4 alkyl. 
The term "alkoxy" refers to oxygen substituted alkyl, for 
example, of the formulas -OR or -ROR', wherein R and 
R' are each independently selected from lower alkyl and 
5 wherein the alkoxy group includes four or fewer atoms in the 
chain, including the oxygen atom. The terms "substituted 
alkyl" and "substituted alkene" refer to alkyl and alkene, 
respectively, substituted with one or more simple 
substitutents, such as but not limited to, C3-C6 cycloalkyl, 
10 e.g., cyclopropyl, cyclobutyl, and the like; acetylene; cyano; 
alkoxy, e.g., methoxy, ethoxy, and the like; lower 
alkanoyloxy, e.g., acetoxy; hydroxy; carboxyl; amino; lower 
alkylamino, e.g., methylamino; ketone; halo, e.g. chloro or 
bromo; phenyl; substituted phenyl, and the like. The term 
15 "lower alkanoyloxy" refers to Cl-C4 alkanoyloxy. The term 
"lower alkylamino" refers to Cl-C4 alkylamino. The term 
"substituted phenyl" refers to phenyl substituted with one or 
more simple substitutents, such as but not limited to lower 
alkyl, hydroxy, carboxyl, halo, sulfato, sulfonyloxy, amino, 
20 alkoxy, and the like. 
In one preferred embodiment of the invention, the com-
pounds have the formula (Ia): 
R3 is selected from the group consisting of methylene, 25 
ketone, and methyl; 
R4 is absent when R3 is methylene or ketone, or when R3 
is methyl, R4 is selected from the group consisting of 
hydrogen, lower alkyl, alkoxy, lower alkanoyloxy, hydroxy, 
carboxyl, amino, lower alkylamino, and halo, or R4 is an 30 
oxygen atom and together with the ClO atom to which R4 is 
attached and Rs comprises a heterocyclic ring and the 
double bond between ClO and R3 , C9 and ClO, or ClO and 
Rs is absent; 
wherein: 
R1 , R2 , R3 , R4 , R6 , and Y are the same as defined above, 
and R7 is a substituent introduced by Michael Addition of 
nucleophiles to the double bond between C3 and C4 when 
present, such as, but not limited to hydroxy, lower alkoxy, 
e.g., methoxy, lower alkanoyloxy, e.g., acetoxy, amino, 
lower alkyl amino, e.g. methyl amino, carboxyl, acetylene, 
Y is selected from the group consisting of Cl-C6 alkyl or 35 
C2-C6 alkene terminating in an amide group -CONH2 , a 
nitrile group -CN, or an acid group(s), including, but not 
limited to carboxylic acid group C02 H, sulfonic acid group 
S03H, carbodithioic acid group CSSH, or phosphoric acid 
group PO(OH)2 , or salts of these acidic groups, or 40 cyano, lower alkyl, lower alkene, cycloalkyl, e.g., 
cyclopropyl, and the like. In this embodiment of the 
invention, Rs is C4 alkyl or C4 alkene having one or more 
double bonds as indicated by the dotted lines. Further, in this 
embodiment of the invention, Y can be ---(CH2)-C(0)-
Y is-(CH2)n -C(O)-X-, wherein n is an integer from 
1 to 3, X is oxygen or nitrogen, and together with CS atom 
to which Y is attached, the C9 atom, and the ClO atom 
constitute a ring system comprising a 6 to S membered 
lactone or lactam ring, or 
Y is -(CH2)-C(O)-O-, and together with the CS 
atom to which Y is attached, the C9 atom, the ClO atom, and 
Rs constitute a ring system comprising a lactone ring when 
R3 is methyl, R4 is hydroxyl and the double bond between 
ClO and R3 , Rs and ClO or C9 and ClO is absent; 
45 0- and together with the CS atom to which Y is attached, 
C9, ClO, Cl, C2 and C3 atoms, constitute a nine membered 
lactone ring. Still further, in this embodiment of the 
invention, R4 can be oxygen and together with C3 and ClO 
to which it is attached, and Cl and C2, constitute a five 
50 membered tetrahydrofuran ring. 
Rs is selected from the group consisting of C2-CS alkyl, 
C2-CS alkene having one or more double bonds, substituted 
C2-CS alkyl, and substituted C2-CS alkene; 
R6 is a functional group selected from the group consist-
ing of CN, COOH, CSSH, or salts of these acid groups, 55 
CHO, CH2 0H, CONH2 , and CONR2 , wherein R is lower 
alkyl, acyl or H, and optionally a hydrogen atom of a carbon 
atom adjacent R6 may be replaced with identical functional 
groups described above; and 
the broken lines indicate optional double bonds, and 60 
pharmaceutically acceptable salts of the compounds of For-
mula (I). 
As used herein, the term "compound" is intended to refer 
to a chemical entity, whether in the solid, liquid or gaseous 
phase, and whether in a crude mixture or purified and 65 
isolated. The terms "alkyl," "alkene," and "alkoxy" include 
straight chain and branched alkyl, alkene, and alkoxy, 
In this embodiment of the invention, the compounds of 
Formula (Ia) include those compounds wherein R1 is 
methyl, R2 is -CH(CH3 ) (CH2 ) 3 CH(CH3 ) 2 , Y is -CH2 -
C(O)-OH, and R6 is CN. In one aspect of this embodiment 
of this invention, the compounds of Formula (Ia) include 
those compounds wherein R3 is -CH3 , the double bonds 
are absent between R3 and ClO, Cl and ClO, C9 and ClO, 
the double bond is also absent between C3 and C4, R7 is 
hydrogen, and R4 is an oxygen atom and together with C3 
and ClO to which it attached, and Cl and C2, constitute a 5 
membered tetrahydrofuran ring. The compounds of this 
aspect of this embodiment of the invention include com-
pounds in either an R configuration or an S configuration at 
ClO. In another aspect of this embodiment of the invention, 
the compounds of Formula (Ia) include those compounds 
wherein R3 is =CH2 and the double bond is present between 
ClO and R3 , the double bond is absent between Cl and ClO, 
6,011,058 
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embodiment of the invention, the compounds include those 
compounds wherein R3 is -CH3 and the double bond is 
absent between ClO and R3 , the double bond is absent 
between Cl and ClO, the double bond is absent between C9 
the double bond is absent between C9 and ClO, and the 
double bond is present between C3 and C4 with a Z 
configuration. In another aspect of this embodiment of the 
invention, the compounds of Formula (Ia) include those 
compounds wherein R3 is -CH3 , R4 is -H, and the double 
bond is absent between ClO and R3 , the double bond is 
absent between C9 and ClO, the double bond is present 
between Cl and ClO, and the double bond is present 
between C3 and C4 with a Z configuration. This embodi-
ment of the invention includes those compounds in either a 
5 and ClO, and the double bond is absent between C3 and C4. 
In another aspect of this embodiment of the invention, the 
compounds of Formula (Ia) include those compounds 
wherein R3 is -CH3 , the double bonds are absent between 
R3 and ClO, Cl and ClO, and C9 and ClO, the double bond 
Z configuration or an E configuration between Cl and ClO. 
10 is absent between C3 and C4, R7 is -OMe with either an 
R configuration or an S configuration. The compounds of 
this embodiment of the invention include those compounds 
in either an R configuration or an S configuration at ClO. 
In yet another aspect of this embodiment of the invention, 
the compounds of Formula (Ia) include those compounds 
wherein R3 is -CH3 and the double bond is absent between 
ClO and R3 , the double bond is absent between Cl and ClO, 15 
the double bond is present between ClO and C9, and the 
double bond is present between C3 and C4 with a Z 
configuration. This embodiment of the invention includes 
those compounds in either a Z or E configuration between 
C9 and ClO. In yet another aspect of this embodiment of the 20 
invention, the compounds of Formula (Ia) include those 
compounds wherein R3 is =CH2 and the double bond is 
present between ClO and R3 , the double bond is absent 
between Cl and ClO, the double bond is absent between C9 
and ClO, and the double bond is absent between C3 and C4. 25 
In yet another aspect of this embodiment of the invention, 
the compounds of Formula (Ia) include those compounds 
wherein R3 is -CH3 , and the double bond is absent between 
ClO and R3 , the double bond is absent between ClO and C9, 
the double bond is present between Cl and ClO, and the 30 
double bond is absent between C3 and C4. This embodiment 
of the invention includes those compounds in either a Z or 
E configuration between Cl and ClO. In yet another aspect 
of this embodiment of the invention, the compounds of 
Formula (Ia) include those compounds wherein R3 is -CH3 35 
and the double bond is absent between ClO and R3 , the 
double bond is absent between Cl and ClO, the double bond 
is present between ClO and C9, and the double bond is 
absent between C3 and C4. This embodiment of the inven-
tion includes those compounds in either a Z or E configu- 40 
ration between C9 and ClO. In yet another aspect of this 
embodiment of the invention, the compounds of Formula 
(Ia) include those compounds wherein R3 is -CH3 , R4 is 
-H, the double bond is absent between C9 and ClO, and the 
double bond is absent between ClO and R3 , the double bond 45 
is absent between Cl and ClO, and the double bond is absent 
between C3 and C4. This aspect of this embodiment of the 
invention includes those compounds in either an R configu-
ration or an S configuration of 19-Me at ClO. 
In another embodiment of the invention, the compounds 50 
of Formula (Ia) are those compounds wherein R1 is methyl, 
R2 is -CH(CH3 ) (CH2 ) 3 CH(CH3 ) 2 , R6 is CN, Y is 
-CH2-C(O)-O- and together with the CS atom to 
which Y is attached, the C9, and the ClO atoms constitute a 
ring system comprising a 6 membered lactone ring. In one 55 
aspect of this embodiment of the invention, the compounds 
include those compounds wherein R3 is -CH3 and the 
double bond is absent between ClO and R3 , the double bond 
is absent between C9 and ClO, the double bond is absent 
between Cl and ClO and the double bond is present between 60 
C3 and C4 with a Z configuration. In another aspect of this 
In another embodiment of the invention, the compounds 
of formula (Ia) are those compounds wherein R1 is methyl, 
R2 is -CH(CH3 ) (CH2hCH(CH3) 2 , R6 is -CN, R4 is 
-OH, and Y is -CH2-C(O)-X, wherein Xis an oxygen 
atom, and together with the CS atom to which Y is attached, 
the C9, ClO, Cl, C2 atoms, and the C3 atom to which X is 
attached, constitute a 9 membered lactone ring. This 
embodiment of the invention includes those compounds in 
either an R configuration or an S configuration at ClO. 
Examples of compounds exemplary of Formula (I) above 
include, but are not limited to: 
6 (lOR) 
7 (lOS) 
8 
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and the like and pharmaceutically acceptable salts thereof. 
Illustrative examples of the synthesis of CS- and 
CS-substituted seco-cholestane derivatives of Formula (I) 
according to the present invention are given in Scheme 1 of 
6,011,058 
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FIG. 1, and in Schemes 2, 3, 4, and 5 of FIGS. 2, 3, 4, and 
5, respectively, with more detail. 
14 
Referring to FIG. 1 and Scheme 1, generally the com-
pounds of invention can be prepared by pyrolysis of com-
pound 3 (wherein R1 and R2 have the meanings ascribed 5 
above, n is an integer from 1 to 3, and X is oxygen or 
nitrogen) under conditions sufficient to open rings A and B 
Scheme 5 of FIG. 5. Cholesteryl acetate and derivatives 
thereof (i.e., in which n is 2 or 3 and/or X is nitrogen) are 
commercially available or can be produced using known 
techniques (see references above). 
For example, referring to Scheme 5 of FIG. 5, compound 
3 can be prepared by ozonolysis of cholesteryl acetate 
(Lettre, H., Mathes, K., Wagner, M., Liebigs Ann. Chem., 
1967, 703, 147-151) under conditions sufficient to form the 
keto acid thereof (Compound 1). The keto acid 1 is then 
to give a side chain containing a cyano group, while leaving 
the cholesteryl C and D rings and side chain (R2) intact. R1 , 
R2 , R3 , R4 and Y of the reaction product have the meanings 
ascribed above. Preferably, the pyrolysis reaction is con-
ducted on a suitable solid support, such as a conventional 
silica gel as known in the art, at a temperature ranging from 
about 100° C. to about 250° C., and more preferably at a 
temperature of about 180° C. 
Referring still the FIG. 1, the resultant reaction product 
can be subjected to additional chemistries as known in the 
art to provide compounds of Formula (I). For example, the 
chain length of the alkyl or alkene chain between ClO and 
CN can be modified to provide a C2-C8, substituted or 
unsubstituted, alkyl or alkene chain using reactants and 
processes as known in the art. See "Comprehensive Organic 
Transformations," Richard C. Larock, VCH Publishers, Inc., 
New York, N.Y., 1989; "Comprehensive Organic 
Chemistry," edited by C. J. Drayton. Sir Derek Barton, F. R. 
S. and W. David Ollis, F. R. S., Perganon Press, 1979, 
Volumes 1-6; "The Organic Chemistry of Drug Synthesis," 
by Daniel Lednier et al., John Wiley & Sons, Inc., 1995, 
Vols. 1-5. In addition, the functionality of the nitrile group 
can also be modified using conventional functionalizing 
agents known in the art and known procedures to provide the 
functionalities as described above with regard to the defi-
nition of R6 . Further, when Y includes a carboxylic acid 
group, the functionality of the carboxylic acid group can also 
be modified using conventional reagents and processes, for 
example, to provide amide, nitrile sulfonic acid groups, 
carbodithioic acid groups, phosphoric acid groups or salts 
thereof. See above references. 
The resultant reaction product typically includes a mix-
ture of compounds such as illustrated in Scheme 2 of FIG. 
2. FIG. 2 illustrates one preferred embodiment of the inven-
tion in which compound 3 is 3-a-azido-B-homo-6-oxa-4-
cholesten-7-one (wherein n is 1 and X is oxygen). The 
compounds can be isolated using conventional purification 
techniques, such as flash chromatography and preparative 
thin layer chromatography, or HPLC techniques. 
The compounds produced in accordance with Scheme 2 
can be subjected to an optional hydrogenation step to 
saturate at least one of the double bonds, for example, 
present in the cyano containing side chain and/or at Cl. 
Exemplary hydrogenation reactions are illustrated in 
Scheme 3 of FIG. 3. 
The compounds produced in accordance with Scheme 2 
can also optionally be subjected to base catalyzed hydrolysis 
or solvolysis to convert R6 from -CN to -COOH or 
-CONH2 . Functional groups can also be introduced at C3 
through the Michael Addition of any nucleophiles to the 
conjugated double bond between C3 and C4. Further, the 
lactone ring in compounds 6, 7, 15 and 16 can be 
hydrolyzed, into -COOH and -OH, which can in turn 
undergo intramolecular Michael additions to the C3 double 
bond to form a 9 membered lactone ring or 5 membered 
tetrahydrofuran ring, respectively. Exemplary base catalysed 
hydrolysis and intramolecular Michael Addition reactions 
are illustrated in Scheme 4 of FIG. 4. 
The starting reactant 3 can be readily prepared from 
cholesteryl acetate or derivatives thereof as illustrated in 
10 subjected to a ring closure step and converted to the lactone 
3~-actoxy-B-homo-6-oxa-4-cholesten-7-one (2). Com-
pound 2 is then exposed to sodium azide at room tempera-
ture to produce 3-a-azido-B-homo-6-oxa-4-cholsten-7-one 
(3), which can be further used as discussed above to produce 
15 the compounds of the invention. 
An alternative way to synthesize the compounds in this 
invention is to use 5,6-seco-5-oxo-3, 4-choleten-6-oic acid, 
which could be readily produced from cholesteryl acetate, as 
a starting material. After protection of the carboxlic acid 
20 group with CH2 N2 , the compound can be converted to an 
oxime, which in the presence of Lewis acid, e.g. PC13 , can 
undergo Beckmann fragmentation reaction (Rodewald, W. 
J., Zaworska, A, Polish J. of Chem, 1980, 54 1147-1155; 
Rodewald, W. J., Achmatowicz, B., Roczniki Chemii, 1972, 
25 46, 203-208) to produce compounds 8 to 12. Another 
alternative way to synthesize the compounds in this inven-
tion is to use Schmidt fragmentation reaction (Barton D., 
and Ollis W. D. et al. Comprehensive Organic Chemistry, the 
Synthesis and Reaction of Organic Compounds, Pergamon 
30 Press, 1979, volume 2, 968-970. Sunaramaiah, A et al. J. 
Indian Chem. Soc. 1976, LIII, 664) of 5,6-seco-5-oxo-3, 
4-choleten-6-oic acid to produce compounds 8 to 12. 
The compounds of Formula (I) can have pharmaceutical 
activity and can be useful in the treatment of a subject 
35 suffering from one or more maladies. Subjects which can be 
treated include animal subjects, typically vertebrates, 
including both mammalian (e.g., human, cat, dog, cow, 
horse, sheep, pig, monkey, ape, etc.) and avian subjects (e.g., 
chicken, turkey, duck, goose, quail, pheasant, etc.). It is 
40 believed, for example, that administering the compounds of 
Formula (I) to a subject can result in inhibition of cdc25 
phosphatase activity, and further that such compounds can 
be useful as cancer therapeutic agents. Moreover, because of 
the specificity of the targeting, use of the compounds of 
45 Formula (I) could possibly reduce some of the deleterious 
side effects that often accompany the use of conventional 
chemotherapeutic agents. Thus the present invention can 
provide methods for treating tumor-bearing subjects in 
which the compounds of the invention are administered to 
50 the subject in need of such treatment in an amount effective 
and in a manner effective to combat such tumors, for 
example, by virtue of targeting cdc25 phosphatase activity in 
the cancer cells. 
The compounds of Formula (I) may be administered per 
55 se or in the form of a pharmaceutically acceptable salt. When 
used in medicine, the salts of the compounds of Formula (I) 
should be both pharmacologically and pharmaceutically 
acceptable, but non-pharmaceutically acceptable salts may 
conveniently be used to prepare the free active compound or 
60 pharmaceutically acceptable salts thereof and are not 
excluded from the scope of this invention. Pharmaceutically 
acceptable salts can be prepared as alkaline metal or alkaline 
earth salts, such as sodium, potassium, or calcium salts of 
the carboxylic acid group. Thus the present invention also 
65 provides pharmaceutical formulations or compositions, both 
for veterinary and for human medical use, which comprise 
the compounds of formula (I) or a pharmaceutically accept-
6,011,058 
15 
able salt thereof with one or more pharmaceutically accept-
able carriers thereof and optionally any other therapeutic 
ingredients. The carrier(s) must be pharmaceutically accept-
able in the sense of being compatible with the other ingre-
dients of the formulation and not unduly deleterious to the 5 
recipient thereof. 
The salts of the present invention may be prepared, in 
general, by reacting a compound of the invention with the 
desired base in solution. After the reaction is complete, the 
salts can be crystallized from solution by the addition of an 
10 
appropriate amount of solvent in which the salt is insoluble. 
The compositions includes those suitable for oral, rectal, 
topical, nasal, ophthalmic, or parenteral (including 
intraperitoneal, intravenous, subcutaneous, or intramuscular 
injection) administration. The compositions may conve-
niently be presented in unit dosage form and may be 15 
prepared by any of the methods well known in the art of 
pharmacy. All methods include the step of bringing the 
active agent into association with a carrier which constitutes 
one or more accessory ingredients. In general, the compo-
sitions are prepared by uniformly and intimately bringing 20 
the active compound into association with a liquid carrier, a 
finely divided solid carrier or both, and then, if necessary, 
shaping the product into desired formulations. 
Compositions of the present invention suitable for oral 
administration may be presented as discrete units such as 25 
capsules, cachets, tablets, lozenges, and the like, each con-
taining a predetermined amount of the active agent as a 
powder or granules; or a suspension in an aqueous liquor or 
non-aqueous liquid such as a syrup, an elixir, an emulsion, 
16 
In addition to the aforementioned ingredients, the com-
positions of the invention may further include one or more 
accessory ingredient(s) selected from the group consisting of 
diluents, buffers, flavoring agents, binders, disintegrants, 
surface active agents, thickeners, lubricants, preservatives 
(including antioxidants) and the like. 
The therapeutically effective dosage of any specific 
compound, the use of which is in the scope of the present 
invention, will vary somewhat from compound to 
compound, patient to patient, and will depend upon the 
condition of the patient and the route of delivery. As a 
general proposition, a dosage from about 2.5 to about 250 
mg/kg body weight, preferably from about 10 to about 100 
mg/kg, will have therapeutic efficacy. When administered 
conjointly with other pharmaceutically active agents, even 
less of the compounds of formula (I) may be therapeutically 
effective. The compound of Formula (I) may be adminis-
tered once or several times a day. The duration of the 
treatment may be once per day for a period of from two to 
three weeks and may continue for period of months or even 
years. The daily dose can be administered either by a single 
dose in the form of an individual dosage unit or several 
smaller dosage units or by multiple administration of sub-
divided dosages at certain intervals. 
The present invention will be further illustrated by the 
following non-limiting examples, in which "g" means 
grams, "mg" means milligrams, "mmol" means millimoles, 
"ml" means milliliters, "min." means minutes, "hrs" means 
hours, "HCl" means hydrochloric acid, "M" means molar, 
a draught, and the like. 30 "mM" means millimolar, "cm" means centimeters, "mp" 
means melting point, " 0 C." means degrees Celsius, and 
"µm" means micrometers. 
A tablet may be made by compression or molding, option-
ally with one or more accessory ingredients. Compressed 
tablets may be prepared by compressing in a suitable 
machine, with the active compound being in a free-flowing 
form such as a powder or granules which is optionally mixed 35 
with a binder, disintegrant, lubricant, inert diluent, surface 
active agent or dispersing agent. Molded tablets comprised 
with a suitable carrier may be made by molding in a suitable 
machine. 
A syrup may be made by adding the active compound to 40 
a concentrated aqueous solution of a sugar, for example 
sucrose, to which may also be added any accessory 
ingredient(s). Such accessory ingredients may include 
flavorings, suitable preservatives, an agent to retard crystal-
lization of the sugar, and an agent to increase the solubility 45 
of any other ingredient, such as polyhydric alcohol, for 
example, glycerol or sorbitol. 
Formulations suitable for parental administration conve-
niently comprise a sterile aqueous preparation of the active 
compound, which can be isotonic with the blood of the 50 
recipient. 
For the following examples, the starting material choles-
teryl acetate was purchased from Aldrich. Thin layer chro-
matography analysis was performed on aluminum sheets 
precoated with 0.2 mm of silica gel containing 60F254 
indicator. Flash chromatography was run using 230--400 
mesh or 10 micron silica gel. Preparative thin layer chro-
matography was run on Whatman silica gel PKSF 150 A 
glass-coated plates with flourescent indicator, bands were 
visualized by UV light at 254 nm. Proton NMR were 
recorded on 300 MHz spectrometer; 13C NMR and DEPT 
were recorded on 100 MHz spectrometer; the homonuclear 
1H-1H and heteronuclear 1H-13C chemical shift correlated 
2D diagrams were obtained using the standard COSY 90 and 
HMQC pulse sequence, respectively, on 500 MHz spectrom-
eter. Two-dimensional nuclear overhauser spectroscopy 
(NOESY) was also recorded on 500 MHz spectrometer. 
High resolution mass spectra were obtained by EI or CI. 
HT-29 human colon cancer cells and A549 human lung 
adenocarcinoma cells were purchased from the American 
Tissue Type Collection (Rockville, Md.). The cell were 
maintained in Dulbecco's modified Eagle's media (DMEM) 
containing 10% fetal bovine serum and harvested with 
Nasal spray formulations comprise purified aqueous solu-
tions of the active agent with preservative agents and 
isotonic agents. Such formulations are preferably adjusted to 
a pH and isotonic state compatible with the nasal mucous 
membranes. 
55 0.05% trypsin and 0.5 mM EDTA before becoming conflu-
ent. 
Formulations for rectal administration may be presented 
as a suppository with a suitable carrier such as cocoa butter, 
or hydrogenated fats or hydrogenated fatty carboxylic acids. 
Ophthalmic formulations are prepared by a similar 60 
method to the nasal spray, except that the pH and isotonic 
factors are preferably adjusted to match that of the eye. 
Topical formulations comprise the active compound dis-
solved or suspended in one or more media such as mineral 
oil, petroleum, polyhydroxy alcohols or other bases used for 65 
topical formulations. The addition of other accessory ingre-
dients as noted above may be desirable. 
In the Examples below, the compound designations have 
the meanings ascribed above. 
Synthesis 
acid (1) 
EXAMPLE 1 
Synthesis of Pyrolysis Precursor 
of 3-~-Acetoxy-5, 6-seco-5-oxocholestan-6-oic 
Ozone was passed into a stirred and cooled (chloroform/ 
dry ice bath) solution of cholesteryl acetate (12 g, 28 mmol) 
in 300 ml petroleum ether for 30 min until the solution 
turned into baby blue. Piperidine (5 ml, 50 mmol) was then 
6,011,058 
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EXAMPLE 2 
Syntheses and Purification of Seco-Cholestane 
added dropwise over 3 minutes. The volume of solution was 
reduced to 100 ml after being stirred and warmed in room 
temperature for 3 hrs. The white precipitate was separated 
and washed with 2 M HCl (3x25 ml) and with water (lx30 
ml) to obtain the free acid. Flash chromatography of the 5 Derivatives (Compounds 4--12) 
crude acid over silica gel (5x40 cm), using hexane-EtOAC A solution of 3 (440 mg, 1 mmol) in 1.5 ml EtOAC was 
(3:1), afforded 1 (5.5 g, 41 %) as a colorless crystal m.p. poured onto 1.5 g silica gel (0.040--0.063 mm, EM Science 
115-117° C.; FTIR (neat film) umax [ cm-1] 3400, 2960, Co.). The silica gel was allowed to evaporate the solvent in 
2868, 1736, 1716, 1249; 1H NMR (CDCl3, 300 MHz) the hood. Then the 3-a-azido-B-homo-6-oxa-4,5-cholesten-
o[ppm]): 9.89(broad), 5.29 (brs, lH), 3.11 (dd, lH, 1=14.4, 10 7-one (3) coated silica gel was heated in a preheated oven at 
4.3 Hz, 2.33 (d, lH, 1=14.5 Hz), 2.08 (s, 3H), 0.99 (s, 3H), 180° C. for 1 hour, then extracted with EtOAc (50 mL) and 
0.88 (d, 3H, 1=6.4 Hz), 0.83 (d, 6H, 1=6.6 Hz), 0.65 (s, 3H); methanol (2x5 mL). The resulting solutions were combined 
13C NMR and DEPT (CDCl3, 100 Hz) o216.4(C), 178.6(C), and concentrated in vacuo to yield a residue which was 
170.3(C), 73.S(CH), 55.9(CH), 54.4(CH), 52·3(C), 43 ·1 subject to column chromatography (silica gel 230-400 
(CH2), 42.S(C), 41.S(CH), 39.7(CH2), 39.4(CH2), 35.9 h h /E OAC 20 l 3 ) ff d ( ) (CH2), 35.7(CH), 35.S(CH), 34.4(CH2), 34.l(CH2), 27.9 15 mes , exane t = : - :1 to a or 4 25 mg, 6.28% 
(CH) 27 9(CH ) 25 l(CH ) 24 3 (CH ) ( ) and 249 mg of crude mixture of compounds 5-12, which , · 2 , . 2 , . 2 , 23.7 CH2 , 23.0 (CH2), 22.8(CH3), 22.5(CH3), 21.5 (CH3), 18.5(CH3), 17.6 were further purified carefully by flash chromatography on (CH3), 11.6(CH3); EIMS (I=l.7v), m/z (relative intensity) silica gel (10 microns), and preparative thin layer chroma-
416.4 (M+, 43), 398.4 (M+-H20, 21), 306.3 (34), 247.3 (97), tography (silica gel, Whatman Co., Hexane/Et0Ac=2:1) for 
110.1 (100); CIMS m/z (1=2.1 v), m/z (relative intensity) 20 several times to afford 5 (56 mg, 13.5%), 6 (44 mg, 10.7%), 
417.4 (M++l, 88), 399.3 (100), 357.3 (40), 331.3 (45). 7 (10.0mg, 3.61%), 8 (51mg,12.3%), 9 (40 mg, 9.3%), 10 
Synthesis of 3-~-Acetoxy-B-homo-6-oxa-4-cholesten-7-one (38 mg, 9.2%). Compounds 11and12 are very likely to form 
(2) in the pyrolysis process. However, the yield was low 
SOC12 (0.8 ml, 10 mmol) in 2 ml CH2Cl was added because there is only one proton at C9 of the pyrolysis 
dropwise to a stirred and cooled (0° C.) solution of 1 (2.3 g, 25 precursor. 6-0xa-2, 3-4, 5-cholest-dien-7-one ( 4) was 
5 mmol) in 12 ml CH2Cl2. After the mixture was stirred at obtained as colorless oil: FTIR (neat film) umax [cm-
1]: 
0° C. for 30 min. 0.1 ml of pyridine was added and the 2947, 2847, 1768, 1657; 1H NMR (CDC13, 300 MHz) o 
resulting mixture was stirred at room temperature for 2 hrs. [ppm]: 5.91 (ddd, lH, 1=5.7, 3.6, 3.5 Hz), 5.69 (d, lH, 1=5.5 
Then the solvent was evaporated in vacuo to yield a residue Hz), 5.67 (ddd, lH, 1=5.7, 5.4, 2.5 Hz), 2.50 (d, lH, 1=12.3 
which was chromatographed on silica gel to yield 2 (1.92 g, 30 Hz), 2.37 (d, lH, 1=12.4 Hz), 2.47 (d, lH, 1=18.3 Hz), 2.27 
78%) as colorless oil: [a]20D +17.7° (c 0.3, CHC13); uv umax (d, 1=17.5, 2.8 Hz), 1.02 (s, 3H), 0.89 (d, 3H, 1=6.5 Hz), 0.86 (CHC13) 241.6 nm (E=358); FTIR (neat film) umax [cm-1]: (d, 6H, 1=6.5 Hz), 0.68 (s, 3H); 
13C NMR and DEPT 
2939, 2873, 1766, 1740, 1667, 1648, 1375, 1242, 1123; 1H (CDCl3, 100 Hz) ol 73.4(C), 157.6(C), 123.S(CH), 123.2 
NMR (CDC13, 300 MHz) o [ppm]: 5.50 (d, lH, 1=4.2 Hz), (CH), 111.6(CH), 56.4(CH), 55.4(CH), 45.9(CH), 43.l(C), 
5.33(t, lH, 1=3.3 Hz), 2.37 (m, 2H), 2.04 (s, 3H), 1.03 (s, 35 39.4(CH2), 39.4(CH2), 37.8(C), 37.2(CH2), 36.3(CH2), 35.6 
3H), 0.88 (d, 3H, 1=6.6 Hz), 0.85 (d, 6H, 1=6.6 Hz) 0.68 (s, (CH), 35.l(CH), 28.0(CH), 27.7(CH2), 25.0(CH2), 23.8 
3H); EI HRMS m/z calcd for C29H460 4 458.3396, found (CH2), 22.8(CH2), 22.8 (CH3), 22.5(CH3), 18.6(CH3), 18.0 
458.3408; EIMS (I=l.7v), m/z (relative intensity) 458.3 (CH3), 17.9 (CH2), 11.9(CH3); EIMS (I=l.3v), m/z (relative 
(22), 498.4 (35), 370.4 (100), 110.1 (62). intensity) 398.4 (M+, 20), 370.4 (10), 329.4 (22), 247.3 (23), 
Synthesis of 3-a-Azido-B-homo-6-oxa-4,5-cholesten-7-one 40 149.2 (40), 109.1 (100); HRMS m/z calcd for C27H420 2 
(3) 398.3185, found 398.3187. 
To a stirred solution of 2.40 g (5 mmol) crude 2 in 35 ml 5,6-Seco-5-oxo-3,4-cholesten-6-oic acid (5) was obtained 
acetone was added dropwise a solution of NaN3 (650 mg, 10 as colorless oil: FTIR (neat film) 2916, 1747, 1712, 1677, 
mmol) in 5 ml water. The reaction mixture was stirred at 1466, 1389, 1228; 1H NMR (CDC13, 300 MHz) o [ppm]: 
room temperature for two hours, poured into 50 ml water, 45 6.73 (m, lH), 5.88 (dd, lH, 1=10.5, 1.5 Hz), 2.40 (dd, lH, 
and extracted with ether. The ethereal extracts were dried 1=15.5, 5.0 Hz), 1.10 (s, 3H), 0.90 (d, 3H, 1=6.5 Hz), 0.86 
over MgS04 and concentrated in vacuo to yield a residue (d, 6H, 1=6.6 Hz), 0.69 (s, 3H); EIMS (1=7.0 v), m/z 
which was subjected to silica gel column chromatography (relative intensity) 416.3 (M+, 17), 398.3 (23), 354.3 (32), 
(230-400 mesh, hexane/EtOAC=lO:l) to afford 3 1.17 g 333.3 (55), 247.3 (63), 110.1 (100); CIMS m/z (1=223 mv), 
(55.3%) as a yellowish oil: [ a]2°D +98.3° (c 0.6, CHC13); uv 50 m/z (relative intensity) 417.3 (7), 399.3 (80), 153.1 (83), 
Amax (CHC13) 245 nm (E=899) ; FTIR (neat film) umax 110.1 (100); HRMS m/z calcd for C27H44Q3 416.3290, 
[cm-1]: 2949, 2873, 2094, 1763, 1670, 1247; 1H NMR found 416.3272. The synthesis of this compound through 
(CDC13, 300 MHz) o [ppm]: 5.43 (d, lH, 1=2.5 Hz), 4.07 (m, other methods were published: Medelovici, M., Glatter, E., 
lH), 2.44 (d, lH, 1=15.0, 11.0 Hz), 2.38 (dd, lH, 1=15.0, 2.0 J. Chem. Soc. Perkin Trans. l, 13, 1992; 1735-1740; Nace, 
Hz), 0.99 (s, 3H), 0.89 (d, 3H, 1=6.5 Hz), 0.84 (d, 6H, 1=6.6 55 H. R., Capstack, E., JOCEAH, J. Org. Chem., 1961, 26, 
Hz), 0.65 (s, 3H); 13C NMR and DEPT (CDC13, 100 Hz) 5020-5024. 
ol 72.l(C), 160.0(C), 113.S(CH), 57.4(CH), 56.3(CH), 55.4 Compound 6 was obtained as colorless prisms: mp.= 
(CH), 51.7(CH), 42.9(C), 39.5(CH2), 39.4(CH2), 39.0(C), 109-111° C.; [a]2°D -42.1° (c 0.73, CHC13); uv Amax 
37.0(CH2), 35.9(CH2), 35.6(CH), 34.9(CH), 33.9(CH2), (CHC13) 240.8 nm (E=89.7); FTIR (neat film) umax [cm-1]: 
28.0(CH), 27.6(CH2), 25.0(CH2), 23.8(CH2), 23.7(CH2), 60 3071, 2956, 2871, 2219, 1720, 1390, 1259; 1H NMR 
22.8(CH3), 22.6(CH3), 22.5(CH2), 19.2(CH3), 18.5(CH3), (CDC13, 300 MHz) o [ppm]: 6.52 (dt, lH, 1=10.8, 7.8 Hz), 
11.8(CH3); EIMS (1=4.0v), m/z (relative intensity) 413.3 5.32 (d, lH, 1=10.5 Hz), 2.60 (dd, lH, 1=17.7, 4.8 Hz), 2.55 
(M+-N2, 46), 399.3(M+-N3,100), 385.3 (38), 353.3 (33), (m, 2H), 2.07 (dt, 2H, 1=12.0, 2.7 Hz), 2.00 (dd, lH, 1=17.7 
247.2 (22); CIMS m/z (I=l.8v), m/z (relative intensity) 11.5 Hz), 1.99-1.77 (m, SH), 1.34 (s, 3H), 0.90 (d, 3H, 1=6.0 
442.2 (M+ +1, 17), 414.2 (M+-N2+l, 100), 399.2 (M+-N3, 65 Hz), 0.86 (d, 6H, 1=6.6 Hz), 0.70 (s, 3H); 13C NMR and 
26); EI HRMS m/z calc. for C27H44N30 2 442.3434, found DEPT (CDC13, 100 Hz) o170.8(C), 154.S(CH), 115.9(C), 
442.3512. 99.8(CH), 86.6(C), 55.7(CH), 55.6(CH), 44.S(CH), 42.S(C), 
6,011,058 
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39.4(CH2), 38.9(CH2), 38.2(CH2), 36.0(CH2), 35.7(CH2), 
35.6(CH), 30.8(CH), 28.0(CH2), 28.0(CH), 25.8(CH2), 23.7 
(CH2), 23.5(CH2), 23.0(CH3), 22.8(CH3 ), 22.8(CH2), 22.5 
(CH3), 18.6(CH3), 11.9(CH3 ); EIMS (I=S.4 v), m/z (relative 
intensity) 413.3 (M+, 5), 398.3 (2), 385.3 (2), 353.3 (5), 5 
333.3 ( 46), 290.2 (21), 248.2 (28), 135.1 (100); CIMS m/z 
(I=3.5 v), m/z (relative intensity) 414.3 (M+ + 1, 100), 396.3 
(37), 333.3 (18), 135.1 (22); EI HRMS m/z calcd. for 
C27H43N02 413.3294, found 413.3253; Anal. Calcd for 
C27H43N02 : C, 78.39; H, 10.48; N, 3.39; found: C, 78.66; 10 
H, 10.71; N, 3.42. 
Compound 7 was obtained as colorless prisms: m.p. 
=132-134° C.; [a]20D +39.3° (c 0.52, CHC13 ); uv Amax 
(CHC13) 242.6 nm (E=152); FTIR (neat film) umax [cm-1 ]: 
2954, 2870, 2224, 1733, 1473, 1389, 1256; 1H NMR 15 (CDC13 , 300 MHz) ll [ppm]: 6.54 (dt, lH, 1=11.0, 7.8 Hz), 
5.35 (d, lH, 1=11.1Hz),2.63 (dd, 2H, 1=15.4, 9.0 Hz), 2.61 
(dd, lH, 1=18.0, 5.1 Hz), 2.02 (dd, lH, 1=18.0, 11.5 Hz), 
2.01-1.68 (m, SH), 1.43 (s, 3H), 0.91(d,3H, 1=6.6 Hz), 0.86 
(d, 6H, 1=6.3 Hz), 0.70 (s, 3H); 13C NMR and DEPT 20 (CDC13 , 100 Hz) ll 170.6(C), 154.4(CH), 115.8(C), 100.2 
(CH), 86.3(C), 55.9(CH), 55.8(CH), 49.3(CH), 42.6(C), 
39.4(CH2), 39.l(CH2), 36.0(CH2), 35.7(CH2), 35.6(CH), 
34.8(CH2), 30.9(CH), 28.l(CH2), 28.0(CH), 26.l(CH2), 
26.0(CH3 ), 23.8(CH2), 23.4(CH2), 22.9(CH2), 22.8(CH3), 25 
22.5(CH3 ), 18.7(CH3 ), 12.0(CH3); EIMS (I=l.4 v), m/z 
(relative intensity) 413.5 (M+, 45), 398.5 (24), 385.5 (27), 
333.4 (31), 248.3 (33), 135.2 (100); EI HRMS m/z calcd. for 
C27H43N02 413.3294, found 413.3308; Anal. Calcd. for 
C27H43N02 : C, 78.39; H, 10.48; N, 3.39; found: C, 78.31; 30 
H, 10.41. N, 3.34. 
Compound 8 was obtained as colorless oil: [a]2°D +31.0° 
(c 0.35, CHC13); uv Amax (CHC13) 240.8 nm (E=814); FTIR 
(neat film) umax [ cm-1 ]: 3380, 3728, 2953, 2874, 2229, 
1703, 1459, 1288; 1 H NMR (CDC13 , 300 MHz) ll [ppm]: 35 
6.50 (dt, lH, 1=11.0, 7.2 Hz), 5.33 (d, lH, 1=11.0 Hz), 
4.93(s, lH), 4.84(s, lH), 2.59 (m, 2H), 2.35 (dd, lH, 1=15.0, 
3.3 Hz), 2.10 (dd, lH, 1=15.0, 11.5 Hz), 2.17 (t, 2H, 1=7.2 
Hz), 1.97 (m, 3H), 0.90 (d, 3H, 1=6.6 Hz), 0.86 (d, 6H, 1=6.6 
Hz), 0.68 (s, 3H); 13C NMR and DEPT (CDC13 , 100 Hz) ll 40 
179.l(C), 154.7(CH), 150.2(C), 116.0(C), 111.2(CH2), 99.8 
(CH), 56.0(CH), 55.3(CH), 51.4(CH), 43.0(C), 39.6(CH2), 
39.5(CH2), 37.2 (CH2), 36.l(CH2), 35.8(CH), 35.7(CH), 
32.5 (CH2), 29.9(CH2), 29.0(CH2), 28.0(CH), 28.0(CH2), 
24.4(CH2), 23.8(CH2), 22.8(CH3 ), 22.5(CH3), 18.7 (CH3), 45 
11.9(CH3); EIMS (I=4.2 v), m/z (relative intensity) 413.3 
(M+, 34), 395.3 (100), 380.3 (25), 354.3 (67), 333.3 (23), 
282.2 (44), 240.2 (40), 43.0 (98); CIMS m/z (I=l.7 v), m/z 
(relative intensity) 414.4 (M+ + 1, 100), 396.4 (78), 378.4 
(18), 349.4 (21); EI HRMS m/z calcd. for C27H43N02 50 
413.3294, found 413.3279; Anal. Calcd for C27H43N02 : C, 
78.39; H, 10.48; N, 3.39; found: C, 78.26; H, 10.39; N, 3.36. 
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calcd for C27H43N02 413.3294, found 413.3312. Anal. 
Calcd. for C27H43N02 :C, 78.39; H, 10.48; N, 3.39; found: 
C, 78.35; H, 10.41; N, 3.40. The configuration of the 1,10 
double bond was assigned as Z for the NOE observed 
between Me-19 and H-1 in the NOESY spectrum. 
Compound 10 was obtained as colorless oil. [a ]20 D 
+26.6° (c 0.30, CHC13); uv Amax (CHC13 ) 255.4 nm 
(E=1212); FTIR (neat film) umax [cm-1 ]: 2946, 2871, 2221, 
1704, 1704, 1647, 1470, 1388, 1294; 1H NMR (CDC13 , 300 
MHz) ll [ppm]: 6.38 (dt, lH, 1=11.1, 7.5 Hz), 5.27 (d, H, 
1=10.4 Hz), 5.17 (t, 1=7.2 Hz), 3.08 (t, 2H, 1=7.2 Hz), 1.60 
(s, 3H), 0.90 (d, 3H, 1=6.6 Hz), 0.86 (d, 6H, 1=6.6 Hz), 0.68 
(s, 3H); EIMS (I=l.5 v), m/z (relative intensity): 413(20), 
395(57), 354(50), 333(12), 282(32), 240(32), 43(100); EI 
HRMS m/z calcd for C27H43N02 413.3294, found 
413.3271; Anal. Calcd. for C27H43N02 :C, 78.39; H, 10.48; 
N, 3.39; found: C, 78.29; H, 10.45; N, 3.42. 
EXAMPLE 3 
Hydrogenation to Produce Additional Cholestane 
Derivatives (Compounds 13, 14, and 15) 
To a solution of Compound 8 (25 mg, 0.061 mmol) in 5 
ml ethyl acetate was added 5 mg of 10% Pd/C. The resulting 
mixture was stirred and hydrogenated for 30 minutes to 
absorb one equivalent of hydrogen, filtered through Celite. 
The filtrate was concentrated in vacuo to yield 23 mg of 
Compound 13 (92%) as colorless oil. [a]20D +38.9° (c 0.15, 
CHC13 ); 1H NMR (CDC13 , 300 MHz) ll [ppm]: 4.84(d, 2H, 
1=22.4 Hz), 2.35(m, 4H), 0.95 (d, 3H, 1=6.6 Hz), 0.85 (d, 
6H, 1=6.6 Hz), 0.75(s, 3H); 13C NMR (CDC13 , 100 MHz) ll 
179.1, 151.3, 119.7, 110.5, 56.0, 55.4, 51.4, 43.1, 39.7, 39.5, 
37.3, 36.1, 35.9, 35.7, 29.3, 28.0, 28.0, 27.9, 26.9, 25.2, 24.4, 
23.8, 22.8, 22.5, 18.7, 17.1, 12.0; EIMS (I=l.4 v), m/z 
(relative intensity): 415(15), 397(53), 369(28), 355(50), 
305(100), 242(80),135(93); EI HRMS m/z calcd for 
C27H45N02 415.3450, found 415.3451. 
To a solution of Compound 6 ( 40 mg, 0.097 mmol) in 8 
ml ethyl acetate was added 10 mg of 10% Pd/C. The 
resulting mixture was stirred and hydrogenated for 40 min-
utes filtered through Celite. The filtrate was concentrated in 
vacuo to yield 38 mg of Compound 15 (92%) as colorless 
oil. [a]2°D -9.2° (c 0.5, CHC13); umax [cm-1 ]: 2952, 2873, 
2250, 1726, 1468, 1388, 1256, 977; 1H NMR (CDC13 , 300 
MHz) ll [ppm]: 2.60(dd, lH, 1=17.7,4.8 Hz), 2.36(t, 2H, 
1=6.6 Hz), 2.06(m, lH), 1.97(dd, lH, 1=17.7, 11.4), 1.31 (s, 
3H), 0.90(d, 3H, 1=6.6 Hz), 0.86(d, 6H, 1=6.6 Hz) 0.70(s, 
3H); EIMS (1=5.9 v), m/z (relative intensity): 415(12), 
400(22), 355(15), 333(38), 248(30), 135(100); CI HRMS 
m/z calcd for C27H46N02 416.3529, found 416.3520. 
To a solution of Compound 8 (25 mg, 0.061 mmol) in 5 
ml ethyl acetate was added 5 mg of 10% Pd/C. The resulting 
mixture was stirred and hydrogenated for 72 hours, filtered 
The relative stereostructure of compound 7 was deter-
mined by single-crystal X-ray diffraction. Compound 7 was 
crystallized in space group P21 2121 with a=6.467(2) A, 
b=34.103(1) A, c=35.479(1) A and refined to a conventional 
factor R=0.0069 for 867 parameters and 10471 reflections 
with F 0 >4 sigma (F 0 ). 
Compound 9 was obtained as colorless oil. [a ]20 D + 12. 7° 
(c 0.15, CHC13); uv Amax (CHC13 ) 255.0 nm (E=1067) ; 
FTIR (neat film) umax [ cm-1 ]: 2955, 2874, 2224, 1711, 1649, 
1470, 1386, 1292; 1H NMR (CDC13 , 300 MHz) ll [ppm]: 
6.37(dt, lH, 1=10.9, 7.7 Hz), 5.27 (dd, H, 1=9.4 Hz, 1.1 Hz), 
5.18 (t, 1=7.7 Hz) 3.10 (dt, 2H, 1=7.7 Hz, 5.5 Hz), 1.67 (s, 
3H), 0.90 (d, 3H, 1=6.6 Hz), 0.86 (d, 6H, 1=6.6 Hz), 0.68 (s, 
3H); EIMS (I=l.1 v), m/z (relative intensity): 413(15), 
395(28), 354(25), 333(12), 240(17), 43(100); EI HRMS m/z 
55 through Celite. The filtrate was concentrated in vacuo and 
separated by reverse phase HPLC using 100% aceonitrile to 
afford 10 mg of compound 145 as colorless oil: 1H NMR 
(CDC13 , 300 MHz) ll[ppm]: 2.31(m, 2H), 1.94(m, lH), 
0.88(d, 1=6.6 Hz, 3H), 0.84(d, 1=6.6 Hz, 3H), 0.78(d, 1=7.2 
60 Hz, 3H), 0.66(s, 3H); 13C NMR (CDC13 , 100 MHz) ll 179.1, 
119.8, 56.1, 54.8, 44.8, 43.0, 39.5, 39.5, 39.4, 36.1, 35.7, 
35.5, 34.9, 31.9, 28.0, 27.9, 26.8, 25.5, 24.8, 23.8, 22.8, 22.5, 
20.2, 18.7, 17.1, 13.6, 11.7; FABMS (I=l.5 V), m/z (relative 
intensity) : 418 (M+ + 1, 25), 400 (100), 382( 45), 356(20); 
65 FAE HRMS calcd for C27H48N02 , 418.3771, found 
418.3679; and 8 mg of compound 14R as colorless oil: 1H 
NMR (CDC13 , 300 MHz) ll[ppm]: 2.32(t, 1=6.9 Hz, 2H), 
6,011,058 
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A solution of 25 mg (0.06 mmol) compound 15 in 10 ml 
of 6% sodium hydroxide in aqueous methanol was heated 
under reflux for overnight. The solution was carefully acidi-
fied with 2 M HCl until there are white precipitates formed. 
2.24(d, 1=4.8 Hz, 2H), 1.94(m, lH), 0.89(d, 1=6.6 Hz, 3H), 
0.88 (d, 1=6.6 Hz, 3H), 0.84(d, 1=6.6 Hz, 3H), 0.67(s, 3H); 
13C NMR (CDCl3, 100 MHz) ol 78.9, 120.1, 56.2, 55.3, 
48.9, 43.0, 39.6, 39.5, 37.1, 36.1, 35.8, 35.5, 29.5, 28.0, 27.9, 
27.4, 25.7, 24.8, 23.8, 22.8, 22.5, 21.0, 19.0, 18.7, 17.1, 11.9; 
FAE MS (I=l.3 V), m/z (relative intensity): 418 (M+ + 1, 32), 
400 (100), 382(55), 356(35) FAE HRMS calcd for 
C27H48N02 , 418.3771, found 418.3683. 
To a solution of a mixture of 9 and 10 (1:1), (40 mg, 0.097 
mmol) in 8 ml ethyl acetate was added 10 mg of 10% Pd/C. 
The resulting mixture was stirred and hydrogenated for 
about 40 min, the reaction was stopped after the reactants 
absorbed one equiv. of hydrogen. The products were filtered 
through Celite and concentrated in vacuo and separated by 
reverse phase HPLC using 100% acetonitrile to afford 20 mg 
5 The solution was extracted with ethyl ether, dried over 
anhydrous sodium sulfate, and evaporated under pressure. 
The residue was purified using preparative TLC to afford 
compound 27 17 mg ( 65%) as colorless oil: FTIR (neat film) 
umax [ cm-1]: 2950, 2870, 1733, 1716, 1459, 1382, 1259; 1 H 
10 
NMR (CDC13, 300 MHz) o [ppm]: 2.58(dd, 1=17.7, 5.1 Hz, 
lH), 2.35(t, 1=7.2 Hz, 2H), 2.04(d, 1=12 Hz, 2H), 1.95(dd, 
1=17.7, 12.0 Hz, lH), 1.30(s, 3H), 0.90(d, 1=6.6 Hz, 3H), 
0.85(d, 1=6.6 Hz, 6H), 0.69(s, 3H) FAE MS (I=0.93v) m/z 
(relative intensity): 435 (M+ + 1, 100), 417(18), 399(15), 
375(12), 323(10). 
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of compound 17 as colorless oil: 1H NMR (CDC13, 300 
MHz) o[ppm]: 5.ll(t, 1=6.9 Hz, lH), 2.30(t, 1=7.2 Hz, 2H), 
2.21-1.93(m, 6H), 1.65(s, 3H), 0.88(d, 1=6.6 Hz, 3H), 
0.84(d, 1=6.6 Hz, 3H), 0.72(s, 3H); 13C NMR (CDC13, 100 
MHz) o 178.2, 139.8, 125.1, 119.7, 56.0, 55.2, 44.4, 43.1, 20 
39.5, 39.5, 37.0, 36.1, 35.7, 34.9, 28.0, 27.9, 26.8, 26.2, 25.6, 
24.4, 23.8, 22.8, 22.5, 19.2, 18.7, 16.6, 11.9; and 19.5 mg of 
compound 18 as colorless oil: 1H NMR (CDC13, 300 MHz) 
o[ppm]: 5.13(t, 1=6.9 Hz, lH), 2.30(t, 1=7.2 Hz, 2H), 
2.26-2.02(m, 4H), 1.94(m, 2H), 1.55(s, 3H), 0.88(d, 1=6.6 25 
Hz, 3H), 0.84(d, 1=6.6 Hz, 3H), 0.72(s, 3H); 13C NMR 
(CDC13, 100 MHz) o 178.5, 140.0, 124.2, 119.9, 56.1, 55.0, 
54.0, 43.1, 39.5, 39.5, 37.3, 36.0, 35.7, 35.2, 28.0, 28.8, 27.8, 
26.5, 25.3, 24.6, 23.8, 22.8, 22.5, 18.7, 16.5, 12.9, 11.9. 
EXAMPLE 5 
Inhibition of CDC25A Phosphatase 
The production and purification of GST fusion protein 
and CDC25A phosphatase inhibition assays were performed 
as previously described. Rice, R. L. et al., A targeted Library 
of Small-Molecule, Tyrosine, and Dual-Specificity Phos-
phatase Inhibitors Derived from a Rational Core Design and 
Random Side Chain Variation, Biochemistry, 1997, 36, 
15965-15974. Briefly, the target enzyme for the assay was 
a glutathione S-transferase (GST) fusion protein containing 
the full length sequence for human cdc25A. The enzyme 
was expressed in Escherichia coli and purified by affinity 
chromatography over glutathione-agarose. Enzyme activity 
was measured under linear reaction conditions with fluores-
EXAMPLE 4 
Base Catalysed Hydrolysis and Michael Addition 
Reactions to Produce 
30 cein diphosphate as the substrate. Reactions were performed 
in the presence of 10 mM dithiothreitol to eliminate oxidant-
type inhibitors from scoring as hits in this assay. A struc-
turally related compound, 3-actoxy-5, 6-seco-5-oxo-
pregnen-6-oic acid, show no inhibitory activity against 
35 CDC25A phosphatase, and was used as negative control in 
the assay. The concentrations of each compound yielding 
50% inhibition of cdc25A was as follows: 
Additional Seco-cholestane Derivatives 
A solution of 25 mg (0.06 mmol)compound 6 in 10 ml of 
0.6% sodium hydroxide in methanol was heated under reflux 
for overnight. The solution was carefully acidified with 2 M 
HCl, then 6 ml of ethyl ether was added to precipitate the 40 
NaCl formed. The solution was filtered, dried over anhy-
drous sodium sulfate, and evaporated at reduced pressure. 
The residue was subjected to silica gel (200-240 mesh) 
column chromatogrphy, eluted with Hexane: Et0Ac=3:1 to 
afford compound 22 (3S, 5 mg, 19%) as colorless crystal: 45 
m.p.=144-145° C.; FTIR (neat film) um= [cm-1]: 2956, 
2937,2859,2250, 1700, 1464, 1383, 1290, 1066; 1HNMR 
(CDC13, 300 MHz) o [ppm]: 4.21 (m, lH), 2.65 (m, 3H), 
2.44(dd, 1=14.6, 4.4 Hz, lH); 1.25(s, 3H), 0.87(d, 1=6.6 Hz), 
0.85(d, 1=6.6 Hz, 6H), 0.68(s, 3H); FAE MS (1=0.93 v) m/z 50 
(relative intensity): 432(40, M++l), 414(100), 396(20), 373 
(20); 
Compound 21 (3R, 3 mg, 12%) as colorless oil: 1H NMR 
(CDC13, 300 MHz) o [ppm]: 4.37 (m, lH), 2.64 (m, 3H), 
2.44(dd, 1 =14.6, 4.4 Hz, lH); 1.25(s, 3H), 0.87(d, 1=6.6 55 
Hz), 0.85(d, 1=6.6 Hz, 6H), 0.68(s, 3H); CIMS (I=5.2 v) m/z 
(relative intensity): 432 (20, M++l), 414(100), 396(10), 
157(10), 124(74); 
Mixture of Compounds 23 and 24 10 mg(37%, 3R: 
3S=l:l) as colorless oil: FTIR (neat film) umax [ cm-1]: 2951, 60 
2869, 1725, 1700, 1466, 1380, 1281, 1111; 1 H NMR 
(CDC13, 300 MHz) o [ppm]: 3.44(m, lH), 3.42(m, lH), 
3.38(s, 3H), 3.37(s, 3H), 2.59(dd, 1=18.0, 4.8, 2H), 2.50, m, 
4H), 1.95(dd, 1=17.4, 12.0, 2H), 1.32(s, 3H), 1.30(s, 3H), 
0.95(d, 1=6.6 Hz, 6H), 0.87(d, 1=6.6 Hz, 12H), 0.68(s, 6H); 65 
FAE MS (I=0.6 v) m/z (relative intensity): 446 (M+ + 1, 100), 
429(45), 413(8), 396(5), 323(47). 
Approximate IC50 
Compound ID (µg per ml) 
8 4.4 
9 >10 
10 10 
7 >50 
13 0.9 
15 0.9 
The IC50s of these compounds showed that the cholesteyl 
side chain is essential for the activity of these compounds. 
The negative control compound, 3-actoxy-5, 6-seco-5-oxo-
pregnen-6-oic acid, lost its activity due to the removal of the 
cholesteryl side chain. In addition, the configuration of the 
cyano-containing side chain is very important for the inhibi-
tory activity of these compound: with the more flexible 
cyano side chain conformation, Compounds 13 and 15 are 
much more potent than the double bond unsaturated com-
pound in this series. Furthermore, the configuration of ClO 
needs to be an R, because compound 7 (lOS) was much less 
active than the lOR isomer, compound 6. 
EXAMPLE 6 
Inhibition of the Growth of Human Colon Cancer 
Cells 
Compounds 6 and 8 prepared as discussed in the preced-
ing examples were also evaluated for potency as inhibitors 
6,011,058 
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of colon cancer cell lines (HT-29). Inhibition of HT-29 colon 
carcinoma cell growth by compounds 6 and S was measured 
in the soft agarose colony-forming assay with continuous 
drug exposure over 7 days as previously described. Alley M. 
C. et al., Activation and inactivation of cancer chemothera- 5 
peutic agents by rat heptocytes cocultured with human 
tumor cell lines, Cancer Res 44:549 (19S4). Briefly, soft-
agarose culture was performed in 35-mm culture dishes 
contained a base layer consisting of 0.5 ml of standard 
culture medium with 0.5% agarose. On day 0, cells in 10 
log-phase growth were dissociated with trypsin and EDTA, 
washed once in growth medium, and subcultured by layer-
ing lxl04 viable cells in 0.5 ml of growth medium, with 
0.3% agarose over each base layer. Cultures containing 
uniformly distributed single-cell suspensions were accepted 15 
for subsequent evaluation. On day one compounds were 
applied to each culture. Cell lines forming a sufficient 
number of detectable colonies were analyzed following 7 
days of incubation. Viable colonies were stained using 
metabolizable tetrazolium salt, and analyzed as described 20 
previously. Alley, M. C. et al., Improved detection of drug 
cytotoxicity in the soft agar colony formation assay through 
use of a metabolizable tetrazolium salt, Life Sci., 3, 
3071-307S, 19S2. FIG. 5 shows that compounds S and 6 
inhibit the proliferation of HT-29 colon cancer cells with 25 
ICso values of 4.S µg/ml and 5 µg/ml, respectively. 
EXAMPLE 7 
Inhibition of Growth of Lung Adenocarcinoma (A-
549) Cells 30 
Compound 6 prepared as discussed in the preceding 
examples were also evaluated for potency as inhibitors of 
the growth of lung adenocarcinoma cell lines. The effect of 
compound 6 was assessed with a clonogenic assay. In brief, 35 
A549 cells in log-phase growth were harvested, resuspended 
in fresh growth media and plated in triplicate in 60 mm 
dishes at cell concentrations estimated to yield 20--100 
colonies per dish following treatment. Four hours after 
plating, cells were either exposed to compound 6 for one day 40 
followed by a wash and culture in fresh medium for 11 days 
(dotted line), or continuously exposed to this compound for 
12 days (solid line). Cells were fixed and stained with 
Coomassie Blue at the end of the 12th day. Colonies with 
greater than 50 cells were scored. FIG. 6 shows that in the 45 
12-day exposure to compound 6, the number of A549 
colonies per dish were reduced 50% at 7 µM, while one day 
exposure to this compound followed by a wash and cultured 
in fresh medium for 11 days, results in 50% reduction of the 
tumor cell colony number per dish at 37 µM. 
The foregoing examples are illustrative of the present 
invention, and are not to be construed as limiting thereof. 
The invention is defined by the following claims, with 
equivalents of the claims to be included therein. 
That which is claimed is: 
1. A compound of the formula (I) 
wherein: 
50 
55 
60 
65 
24 
R1 is selected from the group consisting of H, lower alkyl, 
and alkoxy; 
R2 is selected from the group consisting of Cl-ClO alkyl, 
substituted Cl-ClO alkyl, C2-C10 alkene containing 
one to four double bonds, substituted C2-C10 alkene, 
and Cl-ClO alkyl or C2-C10 alkene having one or 
more heteroatoms selected from the group consisting of 
oxygen atoms and nitrogen atoms inserted into the 
chain thereof, the chain having 10 or less atoms includ-
ing the hetero atoms; 
R3 is selected from the group consisting of methylene, 
ketone, and methyl; 
R4 is absent when R3 is methylene or ketone, or when R3 
is methyl, R4 is selected from the group consisting of 
hydrogen, lower alkyl, alkoxy, lower alkanoyloxy, 
hydroxy, carboxyl, amino, lower alkylamino, and halo, 
or R4 is an oxygen atom which together with the ClO 
atom to which R4 is attached and Rs consists of a 
heterocyclic ring and the double bond between ClO and 
R3 , C9 and ClO, or ClO and Rs is absent; 
Y is selected from the group consisting of Cl-C6 alkyl 
and C2-C6 alkene, said Cl-C6 alkyl or C2-C6 alkene 
terminating in an amide group -CONH2 , a nitrile 
group -CN or an acid group selected from the group 
consisting of carboxylic acids, sulfonic acids, car-
bodithioic acids and phosphoric acids, or salts thereof, 
or 
Y is -(CH2)n -C(O)-X-, wherein n is an integer from 
1 to 3, X is oxygen or nitrogen, and together with CS 
atom to which Y is attached, the C9 atom, and the ClO 
atom constitute a ring system comprising a 6 to S 
membered lactone or lactam ring, or 
Y is -(CH2)-C(O)-O-, and together with the CS 
atom to which Y is attached, the C9 atom, the ClO 
atom, and Rs constitute a ring system consisting of a 
lactone ring when R3 is methyl, R4 is hydroxyl and the 
double bond between ClO and R3 , Rs and ClO or C9 
and ClO is absent; 
Rs is selected from the group consisting of C2-CS alkyl, 
C2-CS alkene having one or more double bonds, 
substituted C2-CS alkyl, and substituted C2-CS alk-
ene; 
R6 is a functional group selected from the group consist-
ing of CN, COOH, CHO, CH2 0H, CONH2 , CSSH, or 
salts of these acid groups, and CONR2 , wherein R is 
lower alkyl, acyl or H, and optionally a hydrogen atom 
of a carbon atom adjacent R6 is replaced with an 
identical functional group; and 
the broken lines indicate optional double bonds, and 
pharmaceutically acceptable salts thereof. 
2. The compound of claim 1, wherein said compound has 
the formula (Ia): 
wherein: 
R1 , R2 , R3 , R4 , R6 , and Y are the same as defined above; 
Rs is C4 alkyl or C4 alkene having one or more double 
bonds as indicated by the dotted lines; and 
6,011,058 
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R7 is a substituent introduced by Michael Addition of 
nucleophiles to the double bond between C3 and C4 
when present. 
26 
bond is absent between Cl and ClO, the double bond is 
present between C9 and ClO, and the double bond is absent 
between C3 and C4. 
3. The compound of claim 2, wherein Y is -CH2-C 
(0)-0H. 
18. The compound of claim 17, wherein the double bond 
5 between C9 and ClO is in a Z configuration. 
4. The compound of claim 2, wherein Y is -CH2-C 
(0)-0- and together with the CS atom to which Y is 
attached, the C9, and the ClO atoms constitute a ring system 
comprising a 6 membered lactone ring. 
5. The compound of claim 2, wherein Y is -CH2-C 10 
(0)-X, wherein Xis an oxygen atom, together with the CS 
atom to which Y is attached, the C9, ClO, Cl, C2 atoms, and 
the C3 atom to which Xis attached, constitute a 9 membered 
lactone ring, when R3 is methyl, R4 is a hydroxyl group, and 
the double bond between C3 and C4 is absent, and the 15 
double bond between ClO and R3, or between Cl and ClO, 
19. The compound of claim 17, wherein the double bond 
between C9 and ClO is in a E configuration. 
20. The compound of claim 3, wherein R3 is -CH3 , R4 
is hydrogen, the double bond is absent between ClO and R3 , 
the double bond is absent between Cl and ClO, the double 
bond is absent between C9 and ClO, and the double bond is 
absent between C3 and C4. 
21. The compound of claim 20, wherein said compound 
is in an R configuration at ClO. 
22. The compound of claim 20, wherein said compound 
is in an S configuration at ClO. 
or between C9 and ClO is absent. 
6. The compound of claim 3, wherein R3 is =CH2 and the 
double bond is present between ClO and R3 , the double bond 
is absent between Cl and ClO, the double bond is absent 
between C9 and ClO, and the double bond is present 
between C3 and C4. 
23. The compound of claim 3, wherein R3 is -CH3 , the 
double bonds are absent between R3 and ClO, Cl and ClO, 
and C9 and ClO, the double bond is also absent between C3 
20 and C4, R7 is hydrogen, R4 is an oxygen atom, and R4 
together with C3 and ClO to which it attached and Cl and 
C2 constitute a 5 membered tetrahydrofuran ring. 
7. The compound of claim 3, wherein R3 is -CH3 and the 
double bond is absent between ClO and R3 , the double bond 
24. The compound of claim 23, wherein said compound 
is in an R configuration at C3. 
25. The compound of claim 23, wherein said compound 
is in an S configuration at C3. 
is absent between C9 and ClO, the double bond is present 25 
between Cl and ClO, and the double bond is present 
between C3 and C4. 26. The compound of claim 4, wherein R3 is -CH3 and 
the double bond is absent between ClO and R3 , the double 
bond is absent between Cl and ClO, the double bond is 
30 absent between C9 and ClO, and the double bond is present 
between C3 and C4. 
8. The compound of claim 7, wherein the double bond 
between Cl and ClO is in a Z configuration. 
9. The compound of claim 7, wherein the double bond 
between Cl and ClO is in an E configuration. 
10. The compound of claim 3, wherein R3 is =CH2 and 
the double bond is present between ClO and R3 , the double 
bond is absent between Cl and ClO, the double bond is 
absent between C9 and ClO, and the double bond is absent 35 
between C3 and C4. 
27. The compound of claim 26, wherein the compound is 
in an R configuration at ClO. 
28. The compound of claim 26, wherein the compound is 
in an S configuration at ClO. 
29. The compound of claim 4, wherein R3 is -CH3 and 
the double bond is absent between ClO and R3 , the double 
bond is absent between Cl and ClO, the double bond is 
absent between C9 and ClO, and the double bond is absent 
11. The compound of claim 3, wherein R3 is -CH3 , and 
the double bond is absent between ClO and R3 , the double 
bond is absent between C9 and ClO, the double bond is 
present between Cl and ClO, and the double bond is absent 
between C3 and C4. 
40 between C3 and C4. 
12. The compound of claim 11, wherein the double bond 
between Cl and ClO is in a Z configuration. 
13. The compound of claim 11, wherein the double bond 
between Cl and ClO is in a E configuration. 
14. The compound of claim 3, wherein R3 is -CH3 , and 
the double bond is absent between ClO and R3 , the double 
bond is absent between Cl and ClO, the double bond is 
present between C9 and ClO, and the double bond is present 
between C3 and C4. 
15. The compound of claim 14, wherein the double bond 
between C9 and ClO is in a Z configuration. 
16. The compound of claim 14, wherein the double bond 
between C9 and ClO is in a E configuration. 
45 
30. The compound of claim 29, wherein the compound is 
in an R configuration at ClO. 
31. The compound of claim 29, wherein the compound is 
in an S configuration at ClO. 
32. The compound of claim 4, wherein R3 is -CH3 , the 
double bonds are absent between R3 and ClO, Cl and ClO, 
and C9 and ClO, the double bond is also absent between C3 
and C4, and R7 is -OMe. 
33. The compound of claim 32, wherein said compound 
50 is in an R configuration at C3. 
34. The compound of claim 32, wherein said compound 
is in an S configuration at C3. 
35. The compound of claim 5, wherein said compound is 
in an R configuration at C3. 
17. The compound of claim 3, wherein R3 is -CH3 , and 55 
the double bond is absent between ClO and R3 , the double 
36. The compound of claim 5, wherein said compound is 
in an S configuration at C3. 
6,011,058 
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37. A compound selected from the group consisting of: 
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0 
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15 
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5 
OH-0 ~ 
o-V 10 
25 (3R) wherein: 
R1 and R2 have the meanings ascribed above; 
R3 is selected from the group consisting of methylene, 
15 ketone, and methyl; 
OH-0 ~ 
N= ,,,,,.·· o-V 
26 (3S) 
HO 
27 
20 
25 
30 
and pharmaceutically acceptable salts thereof. 
35 38. A method of making cholestane derivatives, compris-
ing: 
heating a compound of the formula 
40 
45 
R4 is absent when R3 is methylene or ketone, or R4 is 
selected from the group consisting of hydrogen, lower 
alkyl, alkoxy, lower alkanoyloxy, hydroxy, carboxyl, 
amino, lower alkylamino, and halo when R3 is methyl; 
Y is selected from the group consisting of Cl-C6 alkyl or 
C2-C6 alkene terminating in an amide group 
-CONH2 , a nitrile group -CN, or an acid group, or 
a salt thereof, or 
Y is ---(CH2)-C(O)-X-, wherein n is an integer from 
1 to 3, X is oxygen or nitrogen, and together with CS 
atom to which Y is attached, the C9 atom, and the ClO 
atom constitute a ring system comprising a 6 to 8 
membered lactone or lactam ring; 
R5 is C4 alkyl or alkene; 
R6 is CN; and 
the broken lines indicate optional double bonds, and 
pharmaceutically acceptable salts thereof, 
optionally modifying the chain length between ClO and 
CN to provide a C2-C8 alkyl, C2-C8 alkene having 
one or more double bonds, substituted C2-C8 alkyl, or 
substituted C2-C8 alkene; and 
optionally reacting CN with a functionalizing agent to 
modify CN to a functional group selected from the 
group consisting of COOH, CSSH, or salts of these 
acid groups CHO, CH2 0H, CONH2 , and CONR2 , 
wherein R is lower alkyl, acyl or H, or to replace CN 
and a hydrogen atom of a carbon atom adjacent CN 
with identical functional groups. 
39. The method of claim 38, wherein n is 1 and X is 
oxygen. 
40. The method of claim 38, wherein said heating step is 
50 conducted on a silica gel substrate. 
wherein: 
R1 is selected from the group consisting of H, lower alkyl, 
and alkoxy; 
41. The method of claim 38, wherein said heating step is 
conducted at a temperature ranging from about 100 to about 
250° c. 
42. The method of claim 41, wherein said heating step is 
conducted at a temperature of about 180° C. 
43. The method of claim 39, wherein said product com-
prises a mixture of compounds of formula (I), and wherein 
said process further comprises recovering said compounds. 
44. The method of claim 43, further comprising the step 
of saturating at least one double bond of at least one of said 
recovered compounds. 
R2 is selected from the group consisting of Cl-ClO alkyl, 
55 
substituted Cl-ClO alkyl, C2-C10 alkene containing 
one to four double bonds, substituted C2-C10 alkene, 
and Cl-ClO alkyl or C2-C10 alkene having one or 
more heteroatoms selected from the group consisting of 
oxygen atoms and nitrogen atoms inserted into the 60 
chain thereof, the chain having 10 or less atoms includ-
ing the hetero atoms; 45. The method of claim 43, further comprising the step 
of base catalyzed hydrolysis and Michael addition of at least 
65 one of the said recovered compounds. 
n is an integer from 1 to 3; and 
X is oxygen or nitrogen, 
under conditions sufficient to form at least one compound of 
formula (I) 
46. A pharmaceutical formulation comprising a com-
pound of the formula (I) 
6,011,058 
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wherein: 
R1 is selected from the group consisting of H, lower alkyl, 
and alkoxy; 
5 
10 
R2 is selected from the group consisting of Cl-ClO alkyl, 
substituted Cl-ClO alkyl, C2-C10 alkene containing 15 
one to four double bonds, substituted C2-C10 alkene, 
and Cl-ClO alkyl or C2-C10 alkene having one or 
more heteroatoms selected from the group consisting of 
oxygen atoms and nitrogen atoms inserted into the 
chain thereof, the chain having 10 or less atoms includ- 20 
ing the hetero atoms; 
R3 is selected from the group consisting of methylene, 
ketone, and methyl; 
R4 is absent when R3 is methylene or ketone, or when R3 25 is methyl, R4 is selected from the group consisting of 
hydrogen, lower alkyl, alkoxy, lower alkanoyloxy, 
hydroxy, carboxyl, amino, lower alkylamino, and halo, 
or R4 is an oxygen atom and together with the ClO 
atom to which R4 is attached and Rs comprises a 30 heterocyclic ring and the double bond between ClO and 
R3 , C9 and ClO, or ClO and Rs is absent; 
Y is selected from the group consisting of Cl-C6 alkyl or 
C2-C6 alkene terminating in an amide group 
-CONH2 , a nitrile group -CN, or an acid group 
34 
selected from the group consisting of carboxylic acids, 
sulfonic acids, carbodithioic acids, and phosphoric 
acids, or salts thereof, or 
Y is -(CH2)n -C(O)-X-, wherein n is an integer from 
1 to 3, X is oxygen or nitrogen, and together with CS 
atom to which Y is attached, the C9 atom, and the ClO 
atom constitute a ring system comprising a 6 to S 
membered lactone or lactam ring, or 
Y is -(CH2)-C(O)-O-, and together with the CS 
atom to which Y is attached, the C9 atom, the ClO 
atom, and Rs constitute a ring system comprising a 
lactone ring when R3 is methyl, R4 is hydroxyl and the 
double bond between ClO and R3 , Rs and ClO or C9 
and ClO is absent; 
Rs is selected from the group consisting of C2-CS alkyl, 
C2-CS alkene having one or more double bonds, 
substituted C2-CS alkyl, and substituted C2-CS alk-
ene; 
R6 is a functional group selected from the group consist-
ing of CN, COOH, CSSH, or salts of these acid groups, 
CHO, CH2 0H, CONH2 , and CONR2 , wherein R is 
lower alkyl, acyl or H, and optionally a hydrogen atom 
of a carbon atom adjacent R6 is replaced with an 
identical functional group; and 
the broken lines indicate optional double bonds, or a 
pharmaceutically acceptable salt thereof in a pharma-
ceutically acceptable carrier. 
47. The pharmaceutical formulation of claim 46, wherein 
n is 1 and X is oxygen. 
48. The compound of claim 3, wherein R1 is -CH3 , R2 
is -CH(CH3)(CH2hCH(CH3) 2 , and R6 is -CN. 
* * * * * 
